top of page

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

19.74 -0.17 (-0.85%)

Streaming Delayed Price Updated: 12:19 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday ↗

June 24, 2026

The biotech is floating a relatively sizable secondary share issue.

Via The Motley Fool

MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? ↗

June 04, 2026

This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a year of sharp share price declines.

Via The Motley Fool

Topics Regulatory Compliance

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? ↗

April 18, 2026

Focused on novel immunotherapies for inflammatory diseases, this biotech firm reported significant insider selling in its latest filing.

Via The Motley Fool

Topics Regulatory Compliance

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗

January 09, 2026

Via Stocktwits

MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 ↗

November 13, 2025

Via Stocktwits

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares ↗

April 07, 2026

Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗

February 23, 2026

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown ↗

February 22, 2026

Investors are now turning to Monday’s Investor Day for regulatory clarity, pipeline updates, and key 2026 catalysts.

Via Stocktwits

MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week ↗

February 19, 2026

The investor day update comes after a stock collapse last year following mixed Phase 3 VELA trial results that raised concerns about approval risk.

Via Stocktwits

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Minutes: Why NVDA, TSLA, AAPL, APLD, PANW Are On Traders' Radar Today ↗

February 18, 2026

Data from Stocktwits indicated retail sentiment was stabilizing for SPY and QQQ.

Via Stocktwits

Topics ETFs Economy Lawsuit

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Via Stocktwits

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗

February 17, 2026

Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck.

Via Stocktwits

Topics Intellectual Property

BioTech Breakout: MoonLake Up 30% On FDA Wins ↗

February 03, 2026

Via MarketBeat

MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab ↗

January 15, 2026

The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials.

Via Stocktwits

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Via MarketMinute

Topics Intellectual Property

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗

January 08, 2026

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Via Stocktwits

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

January 08, 2026

Via Chartmill

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Via The Motley Fool

The Best AI for Picking Stocks, Ranked by Performance ↗

October 22, 2025

AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.

Via MarketBeat

Topics Artificial Intelligence ETFs

Which stocks have an unusual volume on Monday? ↗

October 06, 2025

Volume analysis on 2025-10-06: stocks with an unusual volume in today's session.

Via Chartmill

Top 3 Health Care Stocks That Are Preparing To Pump In Q4 ↗

October 06, 2025

Via Benzinga

Unusual volume stocks are being observed in Friday's session. ↗

October 03, 2025

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Via Chartmill

Unusual volume stocks are being observed in Thursday's session. ↗

October 02, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

220 S. Main St.
Colville, WA 99114

Hours: Mon.-Fri., 8 a.m.-5 p.m.

509-684-4567
editor@statesmanexaminer.com

Site by Amber S. King – Creative Design

Home
About
Contact
Submissions

bottom of page